FDA Approves Zevalin® Expanded Label as Part of First-Line Therapy in Treatment of Follicular Non-Hodgkin's Lymphoma
Label Expands Treatable Population To Approximately 43,000 Patients Annually
IRVINE, California – September 4, 2009 –Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, today announced ZEVALIN® (ibritumomab tiuxetan), a CD20-directed radiotherapeutic antibody, received approval from the U.S. Food and Drug Administration (FDA) for an expanded label for the
treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy. This new and expanded indication supplements the 2002 FDA approval of ZEVALIN as treatment for patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma.
